コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 gG1 antibody to oxidized LDL (anti-oxLDL) in cynomolgus monkey.
2 n promising oral bioavailability in rats and cynomolgus monkey.
3 inding, and radiation dosimetry in a healthy cynomolgus monkey.
4 em closely homologous to that of humans, the cynomolgus monkey.
5 s high oral bioavailability in rat, dog, and cynomolgus monkey.
6 r and the most potent vasoconstrictor in the cynomolgus monkey.
7 and the MYOC orthologue was cloned from the cynomolgus monkey.
8 extracellularly in the ciliary muscle of the cynomolgus monkey.
9 A PET study was performed on a cynomolgus monkey.
10 erated and confirmed to be cross-reactive to cynomolgus monkey.
11 IIb, but show higher levels of FcgammaRII in cynomolgus monkey.
12 b/CD18 prevents progression of AKI to CKD in cynomolgus monkeys.
13 labeled material) to two male and two female cynomolgus monkeys.
14 us-sensitive, CD155 transgenic (tg) mice and cynomolgus monkeys.
15 e, after accounting for total volume, in the cynomolgus monkeys.
16 f total volume were determined in rhesus and cynomolgus monkeys.
17 n of B cells and bone marrow plasma cells in cynomolgus monkeys.
18 heavy drinking within the inferior olive of cynomolgus monkeys.
19 ogenitor, CAT6001, in a single-dose study in cynomolgus monkeys.
20 rior cingulate cortex (ACC; Area 24) of male cynomolgus monkeys.
21 f PMNs from the bone marrow of both mice and cynomolgus monkeys.
22 nd pharmacokinetic analysis was performed in cynomolgus monkeys.
23 ow background after intravenous injection in cynomolgus monkeys.
24 e different serum pools from male and female cynomolgus monkeys.
25 surgically menopausal young and middle-aged cynomolgus monkeys.
26 n stimulated gene (ISG) response in mice and cynomolgus monkeys.
27 properties of 12p were assessed in rats and Cynomolgus monkeys.
28 tive primer and probe sets ever reported for cynomolgus monkeys.
29 one marrow transplant recipients of same sex cynomolgus monkeys.
30 g agent and evaluated as PET radioligands in cynomolgus monkeys.
31 d chimerism and renal allograft tolerance in cynomolgus monkeys.
32 s, and DST effectively prevents rejection in cynomolgus monkeys.
33 ian parvovirus (SPV) was first isolated from cynomolgus monkeys.
34 OP) changes in conscious ocular hypertensive cynomolgus monkeys.
35 < 0.001) lowered IOP in ocular hypertensive cynomolgus monkeys.
36 the corresponding biological consequences in cynomolgus monkeys.
37 reaction-mismatched, ABO blood group-matched cynomolgus monkeys.
38 fusion) was performed in one eye each of two cynomolgus monkeys.
39 oxyalaninyl phosphoramidate was evaluated in Cynomolgus monkeys.
40 travitreal (ITV) or intravenous (IV) dose in cynomolgus monkeys.
41 rials of (225)Ac; there are no CD33 sites in cynomolgus monkeys.
42 efrontal and parietal cortex of adult female cynomolgus monkeys.
43 atured good oral bioavailability in mice and cynomolgus monkeys.
44 bies virus-based EBOV vaccine, in rhesus and cynomolgus monkeys.
45 in vivo by administration of LymphoStat-B to cynomolgus monkeys.
46 poor pharmacokinetic profile in both rat and cynomolgus monkeys.
47 mouse model, L(EV) was also tested in three cynomolgus monkeys.
48 fas ligand in blood samples from rhesus and cynomolgus monkeys.
49 f ACAT activity, was significantly higher in cynomolgus monkeys.
50 ntrathecal administration of rituximab using cynomolgus monkeys.
51 lesterol, VLDL/LDL, TG) in both hamsters and cynomolgus monkeys.
52 to identify recently derived retrocopies in cynomolgus monkeys.
53 striatum, amygdala, and extended amygdala of cynomolgus monkeys.
54 jected sequentially into the eyelids of five Cynomolgus monkeys.
55 sion of drug or vehicle, in opposite eyes of cynomolgus monkeys.
56 increased circulating intact FGF21 levels in cynomolgus monkeys.
57 retrocopies, all of which are polymorphic in cynomolgus monkeys.
58 ing strength of cocaine in group-housed male cynomolgus monkeys.
59 erapeutic target for autoimmune diseases, in cynomolgus monkeys.
60 d reduces fever after sublethal challenge in cynomolgus monkeys.
61 administration to lipopolysaccharide-treated cynomolgus monkeys.
62 electrocardiogram parameters in telemetrized cynomolgus monkeys.
63 al mice, mice transgenic for human FcRn, and cynomolgus monkeys.
64 inding protein 2 (MECP2), in both rhesus and cynomolgus monkeys.
65 r cell-mediated killing assay and in vivo in cynomolgus monkeys.
66 tal, 10 PET measurements were conducted on 5 cynomolgus monkeys.
67 I and demonstrated to modulate serum iron in cynomolgus monkeys.
68 on in livers of mice, rats, and dogs but not cynomolgus monkeys.
69 optic nerve margin in the right eyes of four cynomolgus monkeys.
70 hippocampal IRS-1pSer and JNK activation in cynomolgus monkeys.
71 d both blood and bone marrow plasma cells in cynomolgus monkeys.
72 tic cleavage of FGF21 identified in mice and cynomolgus monkeys.
73 ghtly higher than typical IgG1 antibodies in cynomolgus monkeys.
74 e, and selectively reduce LDL-cholesterol in cynomolgus monkeys.
75 unogenic in mice and in Macaca fascicularis (cynomolgus) monkeys.
76 e target tissues, liver, and adipose, and in cynomolgus monkeys a 10 mg/kg oral dose reduced cortisol
78 ant 3-fold increase of ACAT2 protein mass in cynomolgus monkeys, a much greater increase than was fou
80 diet periods, liver biopsies were taken from cynomolgus monkeys, a species highly responsive to dieta
83 n and thrombus detection was investigated in cynomolgus monkeys after insertion of a roughened cathet
84 ifferentiated from the wild-type antibody in cynomolgus monkeys after intravenous administration.
85 n addition, R-13bhad good plasma exposure in cynomolgus monkeys after oral administration, with a C(m
87 nduced ex-vivo platelet aggregation assay in cynomolgus monkeys after oral administration; this activ
88 accine to demonstrate complete protection of cynomolgus monkeys against a homologous MARV challenge.
89 lethal Zaire Ebola virus (ZEBOV) and 100% of cynomolgus monkeys against Lake Victoria Marburg virus (
90 264RAD cross-reacts with human, mouse and cynomolgus monkey alphavbeta6, and inhibits binding to a
91 nt anterograde and retrograde tracers in the cynomolgus monkey and found that all PMC areas are inter
93 ed (>100-fold) stability over 1 or 5, with a cynomolgus monkey and human in vitro plasma half-life of
94 omolgus monkey of those derivatives with low cynomolgus monkey and human intrinsic clearance gave 2',
95 flammatory cytokine induction pathway in the cynomolgus monkey and humans, but not observed systemica
96 to 10,000-fold for CYP1A1 in vivo in rat and cynomolgus monkey and up to 45-fold for CYP1A1 and CYP1A
97 r experience with severe sepsis in two young cynomolgus monkeys and five pigs that were subjected to
98 ormed 305 ovarian stimulations in 128 female cynomolgus monkeys and found that ovarian stimulation ca
99 gulation of the AOX promoter by PPARalpha in cynomolgus monkeys and humans and suggest that this mode
100 of (11)C-Lu AE92686 in the striatum of both cynomolgus monkeys and humans were evaluated by the simp
104 anslate to a pharmacokinetic benefit in both cynomolgus monkeys and mice when constructed on a differ
105 ed the same strategy, with modifications, to cynomolgus monkeys and most recently to renal transplant
106 erapy functionality of SiGdNP were tested in cynomolgus monkeys and pancreatic tumor-bearing mice mod
107 ound 6 had minimal effect on HDL-C levels in cynomolgus monkeys and showed human cadaver skin permeab
108 ntion of acute kidney allograft rejection in cynomolgus monkeys and synergizes with cyclosporine and/
109 ibose (ADPR) and ADP in colonic muscles from cynomolgus monkeys and wild-type (CD38(+/+)) and CD38(-/
110 the pharmacokinetic study of a mAb dosed in cynomolgus monkey, and the results were compared with th
111 olving NK cells, mediate XmAb5574 potency in cynomolgus monkeys, and that enhancing these mechanisms
112 PMNs to LukGH was similar between humans and cynomolgus monkeys, and was greater than that of rabbits
116 nge in resistance significantly increased in cynomolgus monkeys as total volume perfused increased (0
117 d higher titers of toxin-neutralizing Abs in cynomolgus monkeys at 2 wk compared with animals immuniz
121 d 8 has good oral bioavailability in rat and cynomolgus monkey, attractive overall preclinical proper
124 kGH was administered to mice, rabbits, and a cynomolgus monkey by subcutaneous or intradermal injecti
125 tional to Delta n(RNFL)) was measured in two cynomolgus monkeys by enhanced polarization-sensitive op
127 ribution of (125)I-AMG 386 was determined in cynomolgus monkeys by whole-body autoradiography and rad
130 on of 1 mg/kg of body weight fully protected cynomolgus monkeys challenged with aerosolized anthrax s
131 ddition, we investigated the left MD in four cynomolgus monkeys chronically exposed to haloperidol an
134 d chimerism and renal allograft tolerance in cynomolgus monkeys, cyclophosphamide (CP) and total body
135 ements were performed on ex vivo lenses from cynomolgus monkeys (cyno: n = 120; age, 2.7-14.3 years),
136 cine and human therapeutic Ab development in cynomolgus monkeys (cynos) are influenced by immune resp
137 ic (PK) behavior of monoclonal antibodies in cynomolgus monkeys (cynos) is generally translatable to
138 in whole blood isolated from untransplanted cynomolgus monkeys (cynos), in vivo in blood from untran
139 inally, we validated these rodent studies in cynomolgus monkeys, demonstrating that a single 10-Gy do
140 way-derived cells from Ascaris suum-allergic cynomolgus monkeys did not produce appreciable TNF-alpha
141 mouse models of human lymphoma and in normal cynomolgus monkeys disclosed that low doses of veltuzuma
143 ng data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucag
144 alyzed 15 pairs of pregnant and non-pregnant cynomolgus monkeys, each pair of which received embryos
145 its a robust acute pharmacodynamic effect in cynomolgus monkeys (ED50 0.12 mg/kg) and in DIO mice.
148 ic nerve head (ONH) and overlying vessels in cynomolgus monkey eyes were imaged with a fundus camera
150 lecules and their SEFL variants to human and cynomolgus monkey FcgammaRs were evaluated using flow cy
151 tely 40-fold increase in binding affinity to cynomolgus monkey FcRn (C-FcRn) at pH 6.0, with maintena
152 esteryl ester concentrations were highest in cynomolgus monkeys fed cholesterol, despite the fact tha
154 t tetravalent formulations were evaluated in cynomolgus monkeys following a single-dose subcutaneous
155 everal cases of symptomatic SPV infection in cynomolgus monkeys following heart transplantation.
157 ed streptozotocin to induce hyperglycemia in cynomolgus monkeys for 6 months and tested whether high
158 compounds from each series in rat, dog, and cynomolgus monkey has led to the identification of 22 (C
159 ults for human IgG2 and IgG4 obtained in the cynomolgus monkey have to be cautiously interpreted, whe
161 ld prolonged half-life in mice, rabbits, and cynomolgus monkeys; however, the prolongation was less p
162 nd effector functions, whereas, in contrast, cynomolgus monkey IgG2 and IgG4 display strong effector
164 of B cells prior to heart transplantation in cynomolgus monkeys, in addition to conventional posttran
165 odels required dosing every 48 h, studies in cynomolgus monkeys indicate that less frequent dosing ma
166 -MS/MS assay for quantification of human and cynomolgus monkey interleukin 21 (IL-21) was developed,
169 est that depressive behavior in adult female cynomolgus monkeys is similar to that observed in humans
173 arried out metabolic stability studies using cynomolgus monkey liver and intestinal S9 fractions.
175 ve state in a non-human primate species, the cynomolgus monkey (Macaca fascicularis), in a realistic
176 ntia tsutsugamushi (Kp r56) was evaluated in cynomolgus monkeys (Macaca fascicularis) for immunogenic
178 injections in the lateral divisions of MD in cynomolgus monkeys (Macaca fascicularis) to assess the r
180 SEARCH DESIGN AND At baseline, 32 male adult cynomolgus monkeys (Macaca fascicularis) were randomized
181 isms of spread, we infected groups of 5 or 6 cynomolgus monkeys (Macaca fascicularis) with either a w
189 1/2) and the lack of target cell antigens in cynomolgus monkeys may increase toxicity compared with h
192 el of fatal tuberculosis and the established cynomolgus monkey model to design an immuno-chemotherape
195 ge average: 41 +/- 17 years; range: 6-7) and cynomolgus monkey (n = 19; age average: 7.7 +/- 1.8 year
197 receptor availability was assessed in female cynomolgus monkeys (n = 16) with positron emission tomog
204 pharmacokinetic profile in the rat, dog, and cynomolgus monkey of those derivatives with low cynomolg
205 dation of a humanized monoclonal antibody in cynomolgus monkeys over a time period of 12 weeks after
206 important pathogen in surgically manipulated cynomolgus monkeys, particularly with immune compromise.
207 totoxicity in vitro against Daudi cells with cynomolgus monkey peripheral blood mononuclear cells, an
208 e performed in rats (organ distribution) and cynomolgus monkeys (PET/CT imaging) to determine the GLP
210 antibody-dependent monocyte phagocytosis of cynomolgus monkey platelets, and cynomolgus platelet act
211 fusion model of thrombomodulin activation in cynomolgus monkeys, previous intravenous infusion of pha
212 isplacement experiment of [(123)I]ZIENT in a cynomolgus monkey, radioactivity was reduced by 39% in t
213 ure perfusion in one eye of 22 rhesus and 17 cynomolgus monkeys (ranging in age, respectively, from 4
214 given to rhesus macaques on days 42 and 225; cynomolgus monkeys received a booster with either PA or
218 secondary lymphoid organs, and the graft in cynomolgus monkey recipients of heterotopic cardiac allo
220 d in a retrospective analysis on 20 selected cynomolgus monkey recipients of renal xenografts transge
221 uence of alemtuzumab (i) on ex vivo-expanded cynomolgus monkey regulatory T cells (Treg) generated fo
226 al administration of R-13b to castrated male cynomolgus monkeys resulted in a significant decrease in
228 rations by dietary cholesterol, seen only in cynomolgus monkeys, resulted in higher ACAT2 protein lev
229 man (h)FcRn transgenic mice and threefold in cynomolgus monkeys retain efficacy at longer dosing inte
230 noline were detected in pancreas tissue of a cynomolgus monkey sacrificed 24 h after a single adminis
231 say was developed and qualified in human and cynomolgus monkey serum and tissues with a lower limit o
232 antibody and those derived from proteins in cynomolgus monkey serum with either d(2)- or d(0)-formal
234 and phenotypes of TALEN-edited MECP2 mutant cynomolgus monkeys serving as a model for a neurodevelop
237 ging with [(18)F]9-[(18)F]11 in anesthetized cynomolgus monkeys showed high uptake in the putamen wit
238 ic studies in human FcRn transgenic mice and cynomolgus monkeys showed that multiple variants with in
239 ety pharmacology studies with bevacizumab in cynomolgus monkeys showed that this agent is generally w
240 ation of 11 in conscious ocular hypertensive cynomolgus monkeys showed this compound to be efficaciou
241 Administration of bardoxolone methyl to cynomolgus monkeys significantly decreased the protein e
242 er tissues of primates, we gave adult female cynomolgus monkeys six times the human-equivalent dose o
243 However, IL-21 levels were quantified in cynomolgus monkey spleen and colon tissue and normal and
244 idly induce anovulation in a third of female cynomolgus monkeys (stress-sensitive; SS); a third will
245 pproximately 2-fold decrease in clearance in cynomolgus monkey, supporting the notion that modest inc
247 it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepared by c
248 ime profile after oral administration in the cynomolgus monkey that showed a very low peak-to-trough
249 , we evaluated T and B cell alloresponses in cynomolgus monkeys that had received combined kidney/bon
250 in 16 blood group-matched and MLR-mismatched cynomolgus monkeys that were assigned to four different
252 ed hamsters, human CETP transgenic mice, and cynomolgus monkeys, the in vivo efficacy of 12 for raisi
253 HF, we examined tissues of 21 EBOV-infected cynomolgus monkeys throughout time, and also evaluated E
255 acokinetics of two human IgG1 Fc variants in cynomolgus monkey to further clarify the affinity-pharma
256 of dexamethasone (DEX) were administered to cynomolgus monkeys to determine their steroid responsive
257 Heterotopic cardiac allograft outcomes in cynomolgus monkeys treated with a CD154 inhibitor, IDEC-
261 hed streptozotocin-induced diabetic juvenile cynomolgus monkeys underwent transplantation intraportal
262 ST101 were studied in 3xTg-AD mice and young cynomolgus monkeys using a combination of biochemical an
263 e the biological outcome of BAFF blockade in cynomolgus monkeys using a soluble fusion protein consis
264 swine were transplanted into the spleens of cynomolgus monkeys using conventional immunosuppression
265 development of allergic lung inflammation in cynomolgus monkeys using gene expression profiling and t
266 short tandem repeat profiling methodology to cynomolgus monkeys using two human specific alleles, TPO
272 lets transplanted under the renal capsule of cynomolgus monkeys were destroyed within 24 hr by a proc
274 sign in which 31 ovariectomized adult female cynomolgus monkeys were divided into social groups of th
288 cy and was bioavailable in the rat, dog, and cynomolgus monkey when administered orally as a solution
290 was advanced into a pharmacodynamic model in cynomolgus monkeys, where it inhibited adipose 11beta-HS
291 age, obtained from young adult and old adult cynomolgus monkeys, which develop age-related, naturally
292 unodeficiency virus SHIV(89.6P) challenge of cynomolgus monkeys, while native, inactivated, or vector
293 plasma from chimpanzees; gorillas; bonobos; cynomolgus monkeys; wild-type, apoE(-/-), LDLR(-/-), and
299 study evaluates the brain of a rhesus and 11 cynomolgus monkeys with Nissl staining and immunohistoch
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。